10 research outputs found
Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline (GSK) phenotypic screening hit was developed to generate hydroxyethylamine based plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite Plasmodium falciparum at nanomolar concentrations. Lead optimization studies were performed with the aim of improving Plm inhibition selectivity versus the related human aspartic protease cathepsin D (Cat D). Optimization studies were performed using Plm IV as a readily accessible model protein, the inhibition of which correlates with anti-malarial activity. Guided by sequence alignment of Plms and Cat D, selectivity-inducing structural motifs were modified in the S3 and S4 sub-pocket occupying substituents of the hydroxyethylamine inhibitors. This resulted in potent anti-malarials with an up to 50-fold Plm IV/Cat D selectivity factor. More detailed investigation of the mechanism of action of the selected compounds revealed that they inhibit maturation of the P. falciparum subtilisin-like protease SUB1, and also inhibit parasite egress from erythrocytes. Our results indicate that the anti-malarial activity of the compounds is linked to inhibition of the SUB1 maturase plasmepsin subtype Plm X
4-Pyridinio-1,4-Dihydropyridines as Calcium Ion Transport Modulators: Antagonist, Agonist, and Dual Action
A set of six new 4-pyridinio-1,4-dihydropyridine (1,4-DHP) compounds has been synthesized. The calcium channel modulating activity of these compounds was evaluated in an aorta vascular smooth muscle cell line (A7R5), in an isolated rat aortic ring model, and in human neuroblastoma cell lines (SH-SY5Y). The antagonistic effect of these 1,4-DHP was tested by modulating the impact of carbachol-dependent mobilization of intracellular Ca2+ in SH-SY5Y cells. The intracellular free Ca2+ concentration was measured in confluent monolayers of SH-SY5Y cells and A7R5 cells with the Ca2+-sensitive fluorescent indicator Fluo-4 NW. Only four compounds showed calcium channel blocking activity in SH-SY5Y and A7R5 cells as well as in the aortic ring model. Among them, compound 3 was the most active calcium channel antagonist, which had 3 times higher activity on carbachol-activated SH-SY5Y cells than amlodipine. Two of the compounds were inactive. Compound 4 had 9 times higher calcium agonist activity than the classic DHP calcium agonist Bay K8644. The intracellular mechanism for the action of compound 4 using inhibitor analysis was elucidated. Nicotinic as well as muscarinic receptors were not involved. Sarcoplasmic reticulum (ER) Ca2+ (SERCA) stores were not affected. Ryanodine receptors (RyRs), another class of intracellular Ca2+ releasing channels, participated in the agonist response evoked by compound 4. The electrooxidation data suggest that the studied compounds could serve as antioxidants in OS
Synthesis and Evaluation of Reducing Capacity and Calcium Channel Blocking Activity of Novel 3,5-Dipropargylcarbonyl-Substituted 1,4-Dihydropyridines
Novel pyridinium salts on the basis of 4-(3-pyridyl)-3,5-dipropargylcarbonyl-1,4-dihydropyridine were obtained by quaternisation of pyridine moiety with different alkyl halides. The reducing capacity of the synthesized compounds was evaluated using phosphomolybdenum complex method. The obtained results confirmed that all tested compounds possessed reducing capacity. Callcium channel antagonist and agonist activities of the compounds were additionaly assayed by changes in intracellular calcium ion concentration in H9C2 and A7R5 cell lines. The obtained data confirmed that all synthesized 1,4-dihydropyridine derivatives have smouth muscle selective antagonist activities, and in the case of 4-phenyl derivative the activity was 4.7 times higher than that of amlodipine
Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit.
Antimalarial hit 1 SR (TCMDC-134674) identified in a GlaxoSmithKline cell based screening campaign was evaluated for inhibitory activity against the digestive vacuole plasmepsins (Plm I, II, and IV). It was found to be a potent Plm IV inhibitor with no selectivity over Cathepsin D. A cocrystal structure of 1 SR bound to Plm II was solved, providing structural insight for the design of more potent and selective analogues. Structure-guided optimization led to the identification of structurally simplified analogues 17 and 18 as low nanomolar inhibitors of both, plasmepsin Plm IV activity and P. falciparum growth in erythrocytes
Plasmepsin Inhibitory Activity and Structure-Guided Optimization of a Potent Hydroxyethylamine-Based Antimalarial Hit
Antimalarial hit 1SR (TCMDC-134674) identified in a GlaxoSmithKline cell based screening campaign was evaluated for inhibitory activity against the digestive vacuole plasmepsins (Plm I, II, and IV). It was found to be a potent Plm IV inhibitor with no selectivity over Cathepsin D. A cocrystal structure of 1SR bound to Plm II was solved, providing structural insight for the design of more potent and selective analogues. Structure-guided optimization led to the identification of structurally simplified analogues 17 and 18 as low nanomolar inhibitors of both, plasmepsin Plm IV activity and P. falciparum growth in erythrocytes
Synthesis and Studies of Calcium Channel Blocking and Antioxidant Activities of Novel 4-Pyridinium and/or N-Propargyl Substituted 1,4-Dihydropyridine Derivatives
The novel 1,4-DHP derivatives containing the cationic pyridine moiety at the position 4, and the N-propargyl group as a substituent at position 1 of the 1,4-DHP cycle were designed, synthesised, and assessed in biological tests
Plasmepsin Inhibitory Activity and Structure-Guided Optimization of a Potent Hydroxyethylamine-Based Antimalarial Hit
Antimalarial
hit <b>1</b><i><b>SR</b></i> (TCMDC-134674)
identified in a GlaxoSmithKline cell based screening campaign was
evaluated for inhibitory activity against the digestive vacuole plasmepsins
(Plm I, II, and IV). It was found to be a potent Plm IV inhibitor
with no selectivity over Cathepsin D. A cocrystal structure of <b>1</b><i><b>SR</b></i> bound to Plm II was solved,
providing structural insight for the design of more potent and selective
analogues. Structure-guided optimization led to the identification
of structurally simplified analogues <b>17</b> and <b>18</b> as low nanomolar inhibitors of both, plasmepsin Plm IV activity
and <i>P. falciparum</i> growth in erythrocytes
Fragment-Based Discovery of 2‑Aminoquinazolin-4(3<i>H</i>)‑ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV
2-Aminoquinazolin-4(3<i>H</i>)-ones were identified as a novel class of malaria digestive
vacuole plasmepsin inhibitors by using NMR-based fragment screening
against Plm II. Initial fragment hit optimization led to a submicromolar
inhibitor, which was cocrystallized with Plm II to produce an X-ray
structure of the complex. The structure showed that 2-aminoquinazolin-4(3<i>H</i>)-ones bind to the open flap conformation of the enzyme
and provided clues to target the flap pocket. Further improvement
in potency was achieved via introduction of hydrophobic substituents
occupying the flap pocket. Most of the 2-aminoquinazolin-4(3<i>H</i>)-one based inhibitors show a similar activity against
digestive Plms I, II, and IV and >10-fold selectivity versus CatD,
although varying the flap pocket substituent led to one Plm IV selective
inhibitor. In cell-based assays, the compounds show growth inhibition
of Plasmodium falciparum 3D7 with IC<sub>50</sub> ∼ 1 μM. Together, these results suggest 2-aminoquinazolin-4(3<i>H</i>)-ones as perspective leads for future development of an
antimalarial agent
Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine derivatives
The novel 1,4-dihydropyridine derivatives containing the cationic pyridine moiety at the
position 4, and the N-propargyl group as a substituent at position 1 of the 1,4-DHP cycle
were designed, synthesised, and assessed in biological tests. Among all the novel
compounds, the 4-(N-dodecyl) pyridinium group-containing compounds 11 (without the
N-propargyl group) and 12 (with the N-propargyl group) demonstrated the highest
calcium antagonistic properties against neuroblastoma SH-SY5Y (IC50 about 5–14 mM)
and the vascular smooth muscle A7r5 cell (IC50 – 0.6–0.7 mM) lines, indicating that they
predominantly target the L-type calcium channels. These compounds showed a slight total
antioxidant activity. At concentrations close to those of L-type calcium channel blocking
ones, compound 12 did not affect mitochondrial functioning; also, no toxicity was
obtained in vivo. The N-propargyl group as a substituent at position 1 of the 1,4-DHP cycle
did not essentially influence the compounds’ activity. The 4-(N-dodecyl) pyridinium
moiety-containing compounds can be considered as prototype molecules for further
chemical modifications and studies as cardioprotective/neuroprotective agents.This study was supported by ESF project No. 2009/
0217/1DP/1.1.1.2.0/09/APIA/VIAA/031; the EuroNanoMed
project ‘‘CheTherDel’’; Portuguese Research Council
(FCT), Faculty of Medicine, Centre for Neuroscience and
Cell Biology (CNC) and Marine and Environmental
Research Centre (IMAR–CMA) of the University of
Coimbra, Portugal